Genomic medicine reaches HCV-related liver transplantation: Hopes and clinical and public health implications  by Xavier López-Labrador, F. & Berenguer, Marina
EditorialGenomic medicine reaches HCV-related liver transplantation:
Hopes and clinical and public health implications
F. Xavier López-Labrador1,2,3, Marina Berenguer4,5,⇑
1Genomics and Health Area, Molecular Epidemiology, CSISP, Center for Public Health Research, Public Health Department,
Generalitat Valenciana, Spain; 2CIBERESP, National Network Center for Biomedical Research in Epidemiology and Public Health,
Instituto de Salud Carlos III, Spain; 3Department of Microbiology and Institut Cavanilles de Biodiversitat, University of Valencia, Spain;
4Hepatology-Liver Transplantation Unit, Digestive Medicine Service, Hospital Universitari i Politècnic La Fe, Valencia, Spain; 5CIBEREHD, National
Network Center for Biomedical Research in Hepatology and Gastroenterology, Instituto de Salud Carlos III, SpainSee Article, pages 322–327The enormous advances in genomic technologies since the
sequencing of the human genome have propelled biomedical
researchers to examine the role of genetic variation on both the
risk of developing disease and in response to therapies [1].
Although great success has been accomplished with monogenic
disorders, gene-disease association studies on common diseases
have been somewhat disappointing [2]. Examples of success,
such as in hereditary haemochromatosis [3] will probably just
increase with time, especially with accumulating sequenced gen-
omes [4]. To a limited degree, pharmacogenomics have also suc-
ceeded. Examples such as variants of cytochrome P450 linked
with the rate of drug elimination, and associations between geno-
types and treatment response in other diseases such as asthma
and multiple sclerosis hold great promise for the eventual devel-
opment of individually tailored therapies [4].
The past two years turned out to be the time for a genomics
breakthrough on hepatitis C virus (HCV) infection. Chronic hepa-
titis C (CHC) is a major public health problem, due to its progres-
sive nature and the limited efﬁcacy of antiviral therapy.
Mechanisms involved in the achievement of sustained virological
response (SVR) to pegylated interferon plus ribavirin (peg-
IFNa + RBV) include viral genotype, presumably viral sequence
in the Core and NS5A regions, baseline viremia and ﬁbrosis, viral
kinetics, and treatment adherence. A potential role for the genetic
background of the host in determining treatment success as well
as the outcome of viral infection has always been suspected. Dur-
ing 2009 and 2010, data were provided giving strong evidence for
the association of single nucleotide polymorphisms (SNPs) on
chromosome 6 near the IL28B gene (IFNk3, a type III interferon)
with spontaneous and treatment-related clearance of HCV infec-Journal of Hepatology 20
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able (major) alleles, (i) spontaneous clearance of acute infection
is common; and (ii) SVR using either peg-IFNa + RBV or triple
therapy with newer antiviral agents is achieved in a signiﬁcantly
higher number of CHC treated patients [5,6].
Hepatologists were awaiting data extending these important
ﬁndings to the transplant ﬁeld. Indeed, CHC is the leading cause
of liver transplantation (LT) in most centres but recurrent HCV
has a negative impact on the outcome. Moreover, the natural his-
tory of hepatitis C in the graft is highly variable and successful
antiviral therapy targeted to patients with recurrent disease has
only a limited efﬁcacy (12–40% amongst HCV genotype 1 and
60–75% in HCV genotype non-1 infected patients) and poor toler-
ability [7]. LT provides a unique opportunity to investigate the
role of IL28B SNPs both on the course of the disease and in the
response to antiviral therapy. Indeed, HCV-hepatitis progresses
more rapidly in transplanted patients, the time of infection is
known, multiple serum samples are available for testing, and his-
tological assessment is frequent. In addition, in the transplant
model it is possible to investigate the impact of the genetic back-
ground of not only the recipient but also the donor liver, informa-
tion that can be very helpful to advance our understanding of the
biological mechanisms implicated in disease progression and
viral eradication.
In this issue of the Journal, Lange et al. [8] determined the
IL28B rs12979860 genotype of both the allograft and the recipient
in 91 European transplanted patients for end-stage CHC, 47 of
which were treated with peg-IFNa + RBV. The major ﬁndings
can be summarised as follows (i) response to antiviral therapy
was strongly associated with the donor’s IL28B major genotype
(T/T) but only weakly with the recipient’s IL28B genotype; (ii)
recipients with the favourable donor genotype (C/C) had signiﬁ-
cantly higher peak ALT and HCV-RNA concentrations in serum
as compared to those with the unfavourable donor genotypes
C/T or T/T; but no associations were found with the recipient
IL28B genotype; (iii) no association was found between the donor
or recipient IL28B genotype and graft or patient survival; (iv) the
distribution of IL28B alleles in donors was comparable to that of a11 vol. 55 j 270–272
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non-transplanted control population with CHC, whereas the
adverse minor allele (C/T or T/T) was more frequently detected
in patients requiring LT due to end-stage liver disease (ESLD).
Hence, in this study, the major driver of SVR was the genetic
background of the donor graft as opposed to that of the recipient.
Three other studies have reported results on IL28B genotypes
in LT donor/recipient pairs. Fukuhara et al. determined the IL28B
SNPs rs129802750 and rs8099917 SNPs in 67 Japanese living-
donor recipients and 41 donors and found that not only the donor
but also the recipient’s favourable IL28B genotype were signiﬁ-
cantly associated with increased SVR rates, as compared with
the presence of the minor allele (54% vs. 11% in recipients and
44% vs. 9% in grafts with favourable or unfavourable genotypes,
respectively). Combined analysis of recipient/donor genotypes
indicated that ETR/SVR rates in the different possible pairs
(major/major, major/minor or minor/major, and minor/minor
allele combinations) were 90%/56%, 50%/10%, and 0%/0%, respec-
tively [9]. Coto-Llerena et al. determined the IL28B SNPs
rs12979860 and rs8099917 in 128 European recipient/donor
pairs and found that SVR rates were 59% vs. 25% in recipients with
favourable or unfavourable genotypes, respectively, and that a
favourable donor genotype improved the chance for SVR post-
LT [10]. Finally, Charlton et al. studied 189 North-American
donor/recipient pairs, of whom 65 were treated. They found that
a favourable IL28B genotype of the donor and the recipient were
both independently associated with higher rates of SVR [11].
Thus, in the three studies, both recipient and donor genotypes
seemed to inﬂuence the response to peg-IFNa + RBV, in contrast
with the data from Lange et al. Whether these differences may
be explained by the small sample size of the cohorts evaluated,
ethnic differences, or whether it might be due to differences in
the time of treatment initiation or the use of cadaveric vs. liv-
ing-donor organs is at present unknown, but requires further
investigation.
The second aim of the study by Lange et al. was to assess the
impact of IL28B polymorphisms on transplant outcome, including
the natural history of recurrent hepatitis C. The data on the
impact of the genetic background of the host and/or the graft
are unfortunately much less conclusive than that reported on
treatment outcome due to the lack of liver biopsy protocols or
cause of death or graft failure, together with the small sample
size. Interestingly, the two European and the North-American
(but not the Japanese) studies found a signiﬁcantly higher fre-
quency of the unfavourable IL28B genotypes in recipients than
in donors, or in non-LT HCV-infected patients, suggesting that
CHC patients with unfavourable IL28 genotypes may be more
likely to progress to ESLD, a ﬁnding with potential important
public health implications but that requires conﬁrmation in lar-
ger cohorts. In addition, in the study by Charlton et al., analysis
of a subset of patients one year post-transplantation suggested
that recipient (but not donor) unfavourable IL28B rs12979860
genotype was associated with more rapid ﬁbrosis, although not
with decreased survival [11].
The ﬁndings of an association between the IL28B polymor-
phism and response to antiviral therapy obtained in the three
transplant studies parallel those obtained in large cohorts of
CHC immune competent patients or of HCV-HIV coinfected indi-
viduals (reviewed in [5]), highlighting the potential application of
IL28B genotyping for treatment tailoring in all these settings.
How can the effect of IL28B genotype be so strong, even in
individuals with suppression of the cellular immune response?Journal of Hepatology 201A likely explanation is that the enhanced sensitivity to IFNa in
individuals with favourable IL28B genotypes relies more on
innate rather than in cellular adaptive immunity, though the
mechanism behind them remains elusive. Type III IFNs (IFNk1,
IFNk2, and IFNk3, also known as interleukin 29, 28A, and 28B)
are not highly homologous to type I IFNs, but their biological
activities are similar. Although type I and type III IFNs signal
through distinct receptor complexes, they both trigger the Jak-
STAT pathway leading to transcriptional activation of basically
the same set of interferon-stimulated genes (ISGs) to induce an
antiviral state [12]. IFNk was shown earlier to inhibit HCV and
hepatitis B virus (HBV) replication in vitro and, very recently,
HCV replication in humans [13,14]. The current paradigm is that
in IFNa non-responders (NR), baseline intrahepatic ISG expres-
sion is inappropriately pre-activated potentially being not only
ineffective, but also impeding the response to therapy, most
likely by inducing a refractory state of the IFN signalling pathway
[15,16]. Whether the IL28B genotype inﬂuences the expression of
IL28B mRNA or ISGs in the liver is just being elucidated, and
whether ISG expression is driven by the IL28B genotype of the
host, the virus, or both, is unclear [17–19]. To add more pieces
to the puzzle, Shebl et al. found no evidence of an association
between IL28B genotype and expression of ISGs in liver tissue
from subjects uninfected with HCV (N = 960), suggesting that
the association between IL28B genotype and ISG expression in
liver appears to depend on infection with HCV [20]. The only data
available in LT patients suggest that intrahepatic expression of
IL28 mRNA is lower both in donors and recipients carrying
IL28B rs8099917 minor alleles [9]. Importantly, the authors dem-
onstrated microchimerism of donor and recipient cells in the
graft. Their results may explain: (i) partial restoration of sensitiv-
ity to IFNa in an unfavourable IL28B genotype recipient and, con-
versely, in an unfavourable genotype donor background; and (ii)
the previous observation of change in response to therapy after
transplantation occurring in a subset of patients [21]. Thus, opti-
mal graft/recipient matching depending on IL28B alleles may
improve the sensitivity to antiviral therapy post-transplantation.
In conclusion, in this setting of variable responsiveness and
clinical heterogeneity, high-proﬁle pharmacogenomic research
such as that reported by Lange et al. is fundamental for uncover-
ing mechanistic processes in order to potentially achieve an indi-
vidualized approach to antiviral therapy. There are many
questions which remain open at present. Will population-based
genetic screening be useful to identify CHC patients more likely
to progress to ESLD? Unfortunately, as with early gene-associa-
tion studies and most studies performed in the LT setting, small
sample size represents a major limitation to draw strong mean-
ingful conclusions. Do we need to modify the graft allocation sys-
tem by determining the IL28B genotype of potential donors so as
to identify the most favourable grafts for speciﬁc HCV recipients?
This strategy may result in signiﬁcant beneﬁts by improving both
patient outcomes and treatment cost-effectiveness but we still
need more evidence on the independent weight of both the reci-
pient and graft IL28B genotype on CHC graft progression (partic-
ularly compared to donor age) as well as treatment response (vs.
treatment adherence, disease severity at baseline, viral kinetics,
or donor age). Furthermore, whether the same results will be sus-
tained in transplant patients treated with novel direct-acting
antivirals needs to be investigated in the future. Hope is to wish,
and many of us hope that our wish of applying IL28 genetic test-
ing becomes a reality.1 vol. 55 j 270–272 271
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